Brief: Infinity Pharmaceuticals Presents Updated Data From Phase 2 Mario-275 Trial In Urothelial Cancer (Uc) And Phase 2 Mario-3 Trial In Triple Negative Breast Cancer (Tnbc)
27/07/2021 12:33
July 27 (Reuters) - Infinity Pharmaceuticals Inc INFI.O :
* INFINITY PHARMACEUTICALS PRESENTS UPDATED DATA FROM PHASE
2
MARIO-275 TRIAL IN UROTHELIAL CANCER (UC) AND PHASE 2 MARIO-3
TRIAL IN TRIPLE NEGATIVE BREAST CANCER (TNBC)
* INFINITY PHARMA- MARIO-275 AND MARIO-3 TRANSLATIONAL DATA
DEMONSTRATED ON-MECHANISM INCREASED IMMUNE ACTIVATION AND
DECREASED IMMUNE SUPPRESSION
* INFINITY PHARMACEUTICALS - 86.8% OF EVALUABLE 1L PATIENTS
WITH
TNBC IN MARIO-3 ACHIEVED TUMOR REDUCTION WITH A TOTAL DISEASE
CONTROL RATE OF 84.2%
* INFINITY PHARMA- MARIO-275 MEDIAN OVERALL SURVIVAL DATA
SHOW
COMBINATION OF EGANELISIB WITH NIVOLUMAB ACHIEVES 15.4 MONTHS
* INFINITY PHARMACEUTICALS - EXPLORING OPTIMAL STUDY DESIGN
FOR A
POTENTIAL REGISTRATION STUDY AND EXPECT TO PROVIDE A PROGRAM
UPDATE BY END OF 2021
Source text for Eikon: ID:nBwbpGdcWa
Further company coverage: INFI.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Infinity Pharmaceuticals
See all newsBrief: Infinity Pharmaceuticals Filed Voluntary Petition For Relief Under Provisions Of Chapter 11
Brief: Infinity Pharmaceuticals Inc Received Determination Letter From Nasdaq On September 12
Brief: Infinity Pharma Says On Sept 5, 2023, Co Received Letter From Nasdaq Notifying That Listing Of Common Stock Was Not In Compliance With Nasdaq Listing Rule
Brief: Infinity Pharmaceuticals Approved Plan To Reduce Co's Overall Headcount By 21 Positions
U.S. STOCKS ON THE MOVE-General Motors, Estee Lauder, IMAX